Log on / register
Feedback | Support | My details
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J
BMC Psychiatry 2005, 5:26
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
The 3-Year Clinical and Functional Course of Schizophrenia Among Individuals With and Without Diabetes at Study Entry.
Ascher-Svanum H, Zhu B, Ernst FR, Faries DE, Jacobson JG, Doebbeling CC
Prim Care Companion J Clin Psychiatry 2007, 9:122-128
 [PubMed Central] [PubMed] [Related articles]
2.
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.
Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ
Schizophr Res 2007 Feb, 90:186-97
 [PubMed Central] [PubMed] [Related articles]
3.
Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.
Viktil KK, Blix HS, Moger TA, Reikvam A
Br J Clin Pharmacol 2007 Feb, 63:187-95
 [PubMed Central] [PubMed] [Related articles]
4.
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll CU, Frederickson AM, Kane JM, Manu P
Schizophr Res 2007 Jan, 89:91-100
 [PubMed Central] [PubMed] [Related articles]
5.
*** Unable to retrieve article 17070017 ***

 [PubMed Central] [PubMed] [Related articles]
6.
A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.
Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM
J Psychiatry Neurosci 2009 Nov, 34:433-42
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 5 articles in BioMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.